

Reviewer #1:

Scientific Quality: Grade B (Very good)

Language Quality: Grade A (Priority publishing)

Conclusion: Minor revision

Specific Comments to Authors: Please exclude part of the article about cancer vaccine, immunotherapy in early stage HCC and promising trials including tables. These subjects are unnecessary and we don't know if "promising" will become SOC.

We have removed the additional portion regarding cancer vaccine, immunotherapy in early stage and promising trials in this space.

Reviewer #2:

Scientific Quality: Grade B (Very good)

Language Quality: Grade B (Minor language polishing)

Conclusion: Accept (General priority)

Specific Comments to Authors: Well designed Review for the topic

Thank you- no changes are recommended by the reviewer.

Reviewer #3:

Scientific Quality: Grade C (Good)

Language Quality: Grade A (Priority publishing)

Conclusion: Rejection

Specific Comments to Authors: The idea of this article is not novel enough, and it is not deep enough specific

We have added information regarding upcoming treatment regimens in this space, focusing on immunotherapy and MoA of first line drugs. The article also talks about novel treatment strategies that can have potential role in the future and are currently in development.